IDO1 and melanoma: Holmgaard et al. demonstrated that mice with B16 melanoma were resistant to CTLA-4 treatment alone, but were susceptible to CTLA-4 treatment when it was combined with the IDO inhibitor 1-methyltryptophan (1MT) [45].